European COVID-19 Project An ‘Unprecedented’ Exercise In Cooperation
37 Public & Private Partners To Research Potential New Treatments
Executive Summary
Repurposed drugs, new compounds and neutralizing antibodies are among the targets of a new collaborative venture supported by Europe’s Innovative Medicines Initiative.
You may also be interested in...
Pandemic Treaty Could Have IP & Other Implications For Pharma
Equitable access to pandemic medicines and vaccines will be at the core of the WHO’s future global pandemic treaty. Exactly what this will mean for the pharmaceutical industry remains to be seen, but it is likely that companies wanting access to virus samples and other materials will need to agree to benefit sharing in the form of IP and technology transfer.
‘We Need Help,’ Says EMA Chief Amid COVID-19 & Burgeoning Workload
COVID-19, resource constraints and a forthcoming expansion of its responsibilities are piling the pressure on the EU regulator.
How To Avoid Regulatory Mistakes: Experts Put To The Test
Target product profiles, database locks, infarct size as a surrogate endpoint, and changes in the manufacturing process featured in a session of this year’s TOPRA Symposium on dealing with tricky regulatory questions.